COSMYC Trial
Phase 2
50
about 6 years
18+
Male only
1 site in MD
What this study is about
Researchers are testing if a combination of testosterone, ZEN-3694, enzalutamide and ZEN-3694 will reduce tumor size in men with prostate cancer that has become resistant to other treatments. The trial also aims to see if starting with testosterone and ZEN-3694 first might make enzalutamide and ZEN-3694 work better.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Enzalutamide
- 2.Take Luteinizing hormone-releasing hormone (LHRH) analogue
- 3.Take Testosterone cypionate
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
enzalutamide, gonadorelin, Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers) (Androgen Receptor Agonists)
oral (Oral Tablet), injection, intramuscular
Primary: Clinical/radiographic progression free survival (PFS) with BATZEN, Prostate specific antigen (PSA)-Progression free survival (PFS) with ZENZA
Secondary: Number of participants with Objective response to BATZEN and ZENZA, respectively per RECIST 1.1 criteria, Number of participants with treatment-related adverse events, Overall Survival, Progression Free Survival (PFS2) (PSA progression on ZENZA), Quality of Life as assessed by the Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale, Quality of Life as assessed by the Short Form-36 (SF-36)
Oncology